Momentum is gathering hot steam. The Company’s on fire.
I’m glad they listen to investor feedback too. And promptly. I sent that email to Paul about HK just 7 weeks ago, to reinforce that they should give good consideration to HK’s market for Remplir.
Note, separately, they mentioned a separate application for Striate+ due this quarter in last Friday’s (4 April) presentation
I am very pleased they have brought forward the Thai FDA approval expectations to Q2CY25 (this quarter). This was aligned to what I said in the other thread, where I said the previous estimate was a little conservative and that it should be this quarter (likely May 2025) based on timelines. I suspect they likely have gotten positive updates from the Thai FDA in recent days/weeks.
Great work OCC team!
OCC Price at posting:
$1.26 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)